Nasdaq
$0.7500▼ 4.65%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.0MShares out 4.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 3d agoAfter-hours26.10.22 05:30424B3Offering#●●●#●●●#●●●
Dermata Therapeutics, Inc.
Dermata Therapeutics (DRMA) has registered the resale of up to 6,919,560 shares of common stock, consisting of 933,064 previously issued shares and up to 5,986,496 shares issuable upon the exercise of outstanding warrants. This filing relates to a private placement that closed on August 18, 2026, and the company intends to use proceeds from any cash exercise of warrants for working capital.…more
$0.7500-4.65%vs prev closeView filingShare
- 4d agoPre-market26.10.21 13:15filedEFFECTOther
Dermata Therapeutics, Inc.
Dermata Therapeutics' registration statement has been declared effective by the SEC as of October 20, 2026. This effectiveness allows the company to proceed with its planned securities offering and capital raising activities.…more
$0.7500-4.65%vs prev closeView filingShare - 10.9After-hours26.10.10 05:05S-3Offering
Dermata Therapeutics, Inc.
Dermata Therapeutics has filed an S-3 registration statement for the resale of up to 6,919,560 shares of its common stock, previously issued in a private placement. The registration covers 933,064 common shares and additional shares issuable upon the exercise of pre-funded, Series E, Series F, and bank warrants. The company will not receive proceeds from the resale, but will receive cash upon the exercise of the warrants.…more
$0.7500-4.65%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Regular26.10.16 02:29#●●●#●●●
Dermata Therapeutics Shares Surge on Positive Clinical Results for Skin Treatment…more
Dermata Therapeutics announced positive topline results from a clinical study of its Tome Foundational Treatment, showing significant improvements in skin appearance. Following the report of high participant satisfaction and efficacy, the company's stock jumped nearly 34%.…more
$0.7500-4.65%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Pre-market26.10.15 21:10
●●●●●●●● ●●●●● ●●●●●●
Dermata Therapeutics announced that over 71% of participants in its cosmetic clinical study showed overall skin improvements after using Tome Foundational Treatment. The product is currently available for purchase online following these positive clinical findings.…more
$0.7500-4.65%vs prev closeShareBenzinga - 8.21Pre-market26.08.21 21:32
●●●●●●●● ●●●●● ●●●●●●
Dermata Therapeutics has launched preorders for its first direct-to-consumer skincare product, Tome. Shipping for the new product is scheduled to begin on August 25.…more
$0.7500-4.65%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report